Evaxion gets $24M from EIB for AI vaccine research

By The Science Advisory Board staff writers

December 9, 2020 -- The European Investment Bank (EIB) has signed a loan for 20 million euros ($24.1 million U.S.) with Evaxion Biotech to support artificial intelligence (AI) vaccine research.

Evaxion will use the loan to fund research and development for the use of artificial intelligence to determine the most suitable targets for immunotherapies for cancer and infectious diseases. The research could transform the drug discovery process for vaccines and immunotherapies, including those programs targeting Staphylococcus aureus and Pseudomonas aeruginosa.

The move is supported by the Infectious Diseases Finance Facility window under the European Union's (EU) finance for innovation program InnovFin, which provides loans for innovative projects.

CRISPR phage offers precision medicine tool to fight bacterial infections
In an attempt to combat bacterial infections, Locus Biosciences is developing bacteriophage therapies that deliver CRISPR-Cas3 machinery directly to specific,...
U.S. government expands assistance to J&J COVID-19 vaccine research
The Biomedical Advanced Research and Development Authority is expanding its partnership with Johnson & Johnson by providing additional support for...
Immunic gets funding for lead COVID-19 therapeutic candidate
Immunic has inked a 24.5 million euro ($29 million U.S.) financing agreement with the European Investment Bank.

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter